Inventor · disambiguated record
Albert B. Deisseroth
Also filed as: DEISSEROTH ALBERT · DEISSEROTH ALBERT B
33 granted patents·6 pending applications·464 citations·filing 1993–2023
96Inventor score
Top patents by PatentIndex Score
39 records- 0197US5417978ALiposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and useUNIV TEXAS·Filed 1993·Granted May 23, 1995·339 cites·10 claims
- 0292US8119117B2Adenoviral expression vector comprising a CD40L fusion protein adapted to elicit cellular immunityDEISSEROTH ALBERT B·Filed 2003·Granted Feb 21, 2012·37 cites·50 claims
- 0391US8501707B2Mucin antigen vaccineMICROVAX LLC·Filed 2012·Granted Aug 6, 2013·8 cites·27 claims
- 0489US8236295B1Composition comprising an adenoviral expression vector comprising a CD40L fusion protein for generating immune responsesDEISSEROTH ALBERT B·Filed 2012·Granted Aug 7, 2012·9 cites·9 claims
- 0588US10046041B2Methods and compositions for suppressing virulence of methicillin resistant Staphylococcus aureusMICROVAX LLC·Filed 2016·Granted Aug 14, 2018·3 cites·12 claims
- 0688US8742087B2Mucin antigen vaccineMICROVAX LLC·Filed 2013·Granted Jun 3, 2014·4 cites·3 claims
- 0786US10130667B1TAA/ecdCD40L oncolytic virusDEISSEROTH ALBERT B·Filed 2016·Granted Nov 20, 2018·3 cites·3 claims
- 0886US9757438B2Mucin antigen vaccineMICROVAX LLC·Filed 2016·Granted Sep 12, 2017·2 cites·6 claims
- 0986US9533036B2Methods for generating immune responses to influenza antigens with a secretable CD40L fusion proteinTANG YUCHENG·Filed 2006·Granted Jan 3, 2017·8 cites·61 claims
- 1085US8299229B2Mucin antigen vaccineTANG YUCHENG·Filed 2004·Granted Oct 30, 2012·12 cites·30 claims
- 1183US9402920B2Mucin antigen vaccineMICROVAX LLC·Filed 2014·Granted Aug 2, 2016·2 cites·12 claims
- 1283US9353167B2Methods for generating immunity to antigenMICROVAX LLC·Filed 2014·Granted May 31, 2016·3 cites·5 claims
- 1383US8828957B2Methods for generating immunity to antigenDEISSEROTH ALBERT·Filed 2004·Granted Sep 9, 2014·14 cites·47 claims
- 1483US8540979B2Methods of generating immune responses with compositions comprising an adenoviral expression vector comprising a CD40L fusion proteinDEISSEROTH ALBERT B·Filed 2012·Granted Sep 24, 2013·4 cites·6 claims
- 1582US11839655B2Combination cancer therapyMICROVAX LLC·Filed 2018·Granted Dec 12, 2023·1 cites·3 claims
- 1679US10183067B1TAA/CD4OL composition/vaccine for malariaMICROVAX LLC·Filed 2017·Granted Jan 22, 2019·1 cites·11 claims
- 1777US10383932B2Vaccine directed to induction of immune response to protein and glycolipid antigens of bacterial cells through interaction of CD4OL/CD40 receptor axis with complex of glycolipid/CD1d receptor in NKT cells and in dendritic cellsDEISSEROTH ALBERT B·Filed 2016·Granted Aug 20, 2019·1 cites·15 claims
- 1877US9642901B1TAA/CD40L vaccine for malariaMICROVAX LLC·Filed 2013·Granted May 9, 2017·1 cites·4 claims
- 1976US10166284B1Vaccines for herpes simplex virus 1 and 2MICROVAX LLC·Filed 2017·Granted Jan 1, 2019·1 cites·5 claims
- 2076US9458221B2Adenoviral expression vector encoding a CD40L fusion proteinVAXUM LLC·Filed 2013·Granted Oct 4, 2016·2 cites·4 claims
- 2175US2024189422A1Combination cancer therapyMICROVAX LLC·Filed 2023·Application pending·0 cites
- 2272US9526774B1Methods and compositions for suppressing virulence of methicillin resistant Staphylococcus aureusMICROVAX LLC·Filed 2015·Granted Dec 27, 2016·1 cites·3 claims
- 2371US11097001B1Composition and method against tuberculosisMICROVAX LLC·Filed 2017·Granted Aug 24, 2021·1 cites·5 claims
- 2470US2022143171A1Cd40 ligand fusion protein vaccineMICROVAX LLC·Filed 2021·Application pending·0 cites
- 2568US10835589B2Vaccine directed to induction of immune response to protein and glycolipid antigens of bacterial cells through interaction of CD40L/CD40 receptor axis with complex of glycolipid/CD1d receptor in NKT cells and in dendritic cellsDEISSEROTH ALBERT B·Filed 2019·Granted Nov 17, 2020·0 cites·15 claims
- 2668US7304092B1Compounds and methods for treating tumors, cancer and hyperproliferative diseasesUNIV YALE·Filed 2003·Granted Dec 4, 2007·7 cites·28 claims
- 2764US11027006B2Adenoviral vector vaccineVAXUM LLC·Filed 2016·Granted Jun 8, 2021·0 cites·4 claims
- 2864US2023241193A1mRNA VACCINE DESIGN USING MULTIPLE INTERACTING IMMUNO-STIMULATORY PATHWAYS, FOR CANCER AND INFECTIOUS DISEASESMICROVAX LLC·Filed 2023·Application pending·0 cites
- 2962US12427191B1SARS-CoV-2 fusion protein vaccine/regimenMICROVAX LLC·Filed 2022·Granted Sep 30, 2025·0 cites·15 claims
- 3055US11077183B2CD40 ligand fusion protein vaccineMICROVAX LLC·Filed 2016·Granted Aug 3, 2021·0 cites·17 claims
- 3150US11154603B1Burkholderia pseudomallei compositionMICROVAX LLC·Filed 2018·Granted Oct 26, 2021·0 cites·3 claims
- 3247US9889188B1Ebola virus composition/vaccineDEISSEROTH ALBERT B·Filed 2016·Granted Feb 13, 2018·0 cites·10 claims
- 3347US2014127252A1Tularemia-taa/cd40l vaccineDEISSEROTH ALBERT B·Filed 2014·Application pending·0 cites
- 3445US2013149330A1Pharmaceutical compositions and methods of blocking bacillus anthracisMICROVAX LLC·Filed 2013·Application pending·0 cites
- 3544US10174100B1Multivalent DNA composition for Yersinia pestisMICROVAX LLC·Filed 2015·Granted Jan 8, 2019·0 cites·8 claims
- 3644US10149899B1Composition and method against C-difficileDEISSEROTH ALBERT B·Filed 2016·Granted Dec 11, 2018·0 cites·6 claims
- 3743US2006286074A1Methods for immunotherapy of cancerTANG YUCHENG·Filed 2006·Application pending·0 cites
- 3840US10426827B1Dengue hemorrhagic fever virus vaccineMICROVAX LLC·Filed 2015·Granted Oct 1, 2019·0 cites·4 claims
- 3939US10293040B1Pharmaceutical compositions and methods of blocking Bacillus anthracisMICROVAX LLC·Filed 2015·Granted May 21, 2019·0 cites·14 claims
Join the waitlist — get patent alerts
Get an alert when Albert B. Deisseroth files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →